se ha leído el artículo
array:19 [ "pii" => "X0211699502027740" "issn" => "02116995" "estado" => "S300" "fechaPublicacion" => "2002-04-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2002;22 Supl 2:39" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1664 "formatos" => array:3 [ "EPUB" => 194 "HTML" => 1116 "PDF" => 354 ] ] "itemSiguiente" => array:15 [ "pii" => "X0211699502027732" "issn" => "02116995" "estado" => "S300" "fechaPublicacion" => "2002-04-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2002;22 Supl 2:40" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 7906 "formatos" => array:3 [ "EPUB" => 194 "HTML" => 6414 "PDF" => 1298 ] ] "es" => array:8 [ "idiomaDefecto" => true "titulo" => "Fisiopatología del daño renal asociado a proteinuria. Estrategias terapéuticas" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "40" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M. PRAGA" "autores" => array:1 [ 0 => array:1 [ "nombre" => "M. PRAGA" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699502027732?idApp=UINPBA000064" "url" => "/02116995/00000022000000S2/v0_201502091327/X0211699502027732/v0_201502091327/es/main.assets" ] "itemAnterior" => array:15 [ "pii" => "X0211699502027759" "issn" => "02116995" "estado" => "S300" "fechaPublicacion" => "2002-04-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2002;22 Supl 2:37-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2820 "formatos" => array:3 [ "EPUB" => 182 "HTML" => 2236 "PDF" => 402 ] ] "es" => array:8 [ "idiomaDefecto" => true "titulo" => "Implicaciones clínicas y terapéuticas de la hipertrofia ventricular izquierda en la hipertensión" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "37" "paginaFinal" => "38" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "V. BARRIOS" "autores" => array:1 [ 0 => array:1 [ "nombre" => "V. BARRIOS" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699502027759?idApp=UINPBA000064" "url" => "/02116995/00000022000000S2/v0_201502091327/X0211699502027759/v0_201502091327/es/main.assets" ] "en" => array:8 [ "idiomaDefecto" => true "titulo" => "Prevention of chronic renal disease progression" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "39" ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "F. LOCATELLI , L. DE VECCHIO" "autores" => array:1 [ 0 => array:1 [ "nombre" => "F. LOCATELLI , L. DE VECCHIO" ] ] ] ] "textoCompleto" => "NEFROLOGÍA. Vol. XXII. Suplemento 2. 2002 Prevention of chronic renal disease progression F. Locatelli and L. del Vecchio Department of Nephrology and Dialysis. Ospedale A. Manzoni, Lecco. Italy. Preventing renal disease from progressing to endstage renal failure (ESRF) is not only a medical challenge, but also a growing social and economic problem in many countries. The identification and correction of physiological and metabolic hanges that may contribute towards progressive renal deterioration is thus crucial. Proteinuria and hypertension are the major factors contributing to the progression of chronic renal disease and effective antihypertensive therapy is currently the single most important treatment i chronic renal insufficiency (CRI) pateints; this also in the perspective that lowering blood pressure in the major determinant of proteinuria reduction. Some hypertensive agents may be capable of reducing CRI progression not only because of their antihypertensive and antiproteinuric effects, but also because they may halt some of the pathogenetic mechanisms involved in glomerular and tubulo-interstitial renal damage. There seems to be a clear difference in the antiproteinuric capacity of the different classes of antihypertensive drugs, with ACE inhibitors, angiotensin II receptor antagonists (AT1RA) and non-dihydropyridine calcium channel blockers (CCBS) having the greatest capacity to reduce urinary protein excretion. However, it seems that, after a significant decrease in blood pressure, the antiproteinuric effect of all of the antihypertensive drugs became nearly the same, although this should be tested in randomised, controlled trials. According to the results of large trials, ACE inhibitors also significantly reduce the rate of loss of renal function in diabetic and non-diabetic chronic renal diseases; this effect is greatest in patients with substantial proteinuria at baseline. It is worth noting that the HOPE study strongly supported the use of ACE inhibitors as preventive agents for patients at high risk of cardiovascular events (such as CRI patients). AT1RAs have recently been proved of benefit in type 2 diabetic nephropathy. The possible renoprotective effect of CCBs is still controversial. The possibility that combination treatments with some classes of antihypertensive drugs (i.e. ACE inhibitors, CCBs, AT1RAs) may have additive or even synergistic renoprotective effects other than blood presure control is extremely fascinating, also consi- dering that multidrug antihypertensive regimens are required to obtain the present blood pressure target in the majority of patients with CRI; however, this has still to be proved. Dyslipidemia is common in patients with chronic renal disease, especially in those with more severe CRI or the nephrotic syndrome. Since the first observation that lipids accumulate within scarred kidneys, it has been suggested that dyslipoproteinemia contributes towards the progression of glomerular and tubular lesions, which leads to a subsequent deterioration in renal function. While awaiting for the results of ongoing trials about the possible role of statins in the prevention of CRI progression, lipid-lowering therapy can not still be recommended for renoprotection. However, recommendations should also be based on the well established cardiovascular risk associated with hyperlipidaemia. In addition, statins may influence important intracellular pathways that are involved in inflammatory and fibrogenic responses leading to vascular disease. This is likely to be all the more relevant in patients with ESRF, whose cardiovascular morbidity and mortality is considerably increased. Dietary protein restriction is effective in slowing down the rate of CRI progression, but this effect marginally delay the time when ESRF is reached. For this reason, very-low-protein intakes or vegetarian regimens should be considered only in highly motivated patients, without forgetting that the risk of malnutrition. The calcium and phosphorus metabolism seems not to play a major role in the progression of renal injury, at least in the early phase; further studies are needed to elucidate whether lipid abnormalities have a casual role in CRI progression or they are merely a consequence of metabolic derangements. However, given that hyperphosphoremia, hyperparathyroidism and dyslipidemia may contribute to the development of cardiovascular disease in CRI patients, great attention has to be paid to the treatment of these conditions. Finally, it is important to stress that general medical care is a very strong determinant of patient outcome in the conservative phase of CRI treatment. For this reason intervention has to be tailored to each patient in order of not only preserving residual renal function, but also guaranteeing patient well-being 39 " "pdfFichero" => "P7-E193-S140-A3694.pdf" "tienePdf" => true ] "idiomaDefecto" => "en" "url" => "/02116995/00000022000000S2/v0_201502091327/X0211699502027740/v0_201502091327/en/main.assets" "Apartado" => array:4 [ "identificador" => "35407" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Suplementos" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/02116995/00000022000000S2/v0_201502091327/X0211699502027740/v0_201502091327/en/P7-E193-S140-A3694.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699502027740?idApp=UINPBA000064" ]
Idioma original: Inglés
año/Mes | Html | Total | |
---|---|---|---|
2024 Noviembre | 4 | 6 | 10 |
2024 Octubre | 34 | 40 | 74 |
2024 Septiembre | 24 | 23 | 47 |
2024 Agosto | 48 | 60 | 108 |
2024 Julio | 32 | 27 | 59 |
2024 Junio | 41 | 36 | 77 |
2024 Mayo | 58 | 25 | 83 |
2024 Abril | 35 | 36 | 71 |
2024 Marzo | 19 | 22 | 41 |
2024 Febrero | 31 | 38 | 69 |
2024 Enero | 27 | 22 | 49 |
2023 Diciembre | 21 | 20 | 41 |
2023 Noviembre | 31 | 31 | 62 |
2023 Octubre | 25 | 47 | 72 |
2023 Septiembre | 20 | 26 | 46 |
2023 Agosto | 22 | 21 | 43 |
2023 Julio | 28 | 37 | 65 |
2023 Junio | 26 | 12 | 38 |
2023 Mayo | 31 | 24 | 55 |
2023 Abril | 10 | 21 | 31 |
2023 Marzo | 33 | 19 | 52 |
2023 Febrero | 19 | 16 | 35 |
2023 Enero | 28 | 20 | 48 |
2022 Diciembre | 30 | 21 | 51 |
2022 Noviembre | 17 | 19 | 36 |
2022 Octubre | 24 | 41 | 65 |
2022 Septiembre | 25 | 29 | 54 |
2022 Agosto | 30 | 30 | 60 |
2022 Julio | 23 | 41 | 64 |
2022 Junio | 20 | 18 | 38 |
2022 Mayo | 30 | 38 | 68 |
2022 Abril | 27 | 27 | 54 |
2022 Marzo | 40 | 33 | 73 |
2022 Febrero | 21 | 30 | 51 |
2022 Enero | 25 | 31 | 56 |
2021 Diciembre | 32 | 33 | 65 |
2021 Noviembre | 22 | 33 | 55 |
2021 Octubre | 23 | 33 | 56 |
2021 Septiembre | 24 | 28 | 52 |
2021 Agosto | 21 | 24 | 45 |
2021 Julio | 30 | 31 | 61 |
2021 Junio | 20 | 16 | 36 |
2021 Mayo | 26 | 24 | 50 |
2021 Abril | 40 | 30 | 70 |
2021 Marzo | 34 | 7 | 41 |
2021 Febrero | 24 | 14 | 38 |
2021 Enero | 13 | 13 | 26 |
2020 Diciembre | 14 | 14 | 28 |
2020 Noviembre | 18 | 8 | 26 |
2020 Octubre | 20 | 11 | 31 |
2020 Septiembre | 22 | 5 | 27 |
2020 Agosto | 24 | 8 | 32 |
2020 Julio | 13 | 6 | 19 |
2020 Junio | 18 | 13 | 31 |
2020 Mayo | 23 | 13 | 36 |
2020 Abril | 24 | 11 | 35 |
2020 Marzo | 35 | 10 | 45 |
2020 Febrero | 25 | 18 | 43 |
2020 Enero | 27 | 17 | 44 |
2019 Diciembre | 24 | 9 | 33 |
2019 Noviembre | 19 | 11 | 30 |
2019 Octubre | 8 | 6 | 14 |
2019 Septiembre | 13 | 8 | 21 |
2019 Agosto | 6 | 7 | 13 |
2019 Julio | 17 | 13 | 30 |
2019 Junio | 24 | 9 | 33 |
2019 Mayo | 5 | 11 | 16 |
2019 Abril | 30 | 29 | 59 |
2019 Marzo | 12 | 11 | 23 |
2019 Febrero | 5 | 8 | 13 |
2019 Enero | 11 | 9 | 20 |
2018 Diciembre | 23 | 20 | 43 |
2018 Noviembre | 24 | 5 | 29 |
2018 Octubre | 20 | 9 | 29 |
2018 Septiembre | 21 | 6 | 27 |
2018 Agosto | 15 | 10 | 25 |
2018 Julio | 11 | 6 | 17 |
2018 Junio | 16 | 8 | 24 |
2018 Mayo | 15 | 5 | 20 |
2018 Abril | 15 | 3 | 18 |
2018 Marzo | 12 | 5 | 17 |
2018 Febrero | 7 | 1 | 8 |
2018 Enero | 9 | 4 | 13 |
2017 Diciembre | 10 | 5 | 15 |
2017 Noviembre | 8 | 2 | 10 |
2017 Octubre | 12 | 6 | 18 |
2017 Septiembre | 9 | 10 | 19 |
2017 Agosto | 15 | 23 | 38 |
2017 Julio | 20 | 7 | 27 |
2017 Junio | 16 | 4 | 20 |
2017 Mayo | 17 | 4 | 21 |
2017 Abril | 13 | 1 | 14 |
2017 Marzo | 8 | 27 | 35 |
2017 Febrero | 5 | 0 | 5 |
2017 Enero | 7 | 2 | 9 |
2016 Diciembre | 16 | 7 | 23 |
2016 Noviembre | 24 | 5 | 29 |
2016 Octubre | 25 | 4 | 29 |
2016 Septiembre | 23 | 4 | 27 |
2016 Agosto | 64 | 0 | 64 |
2016 Julio | 41 | 0 | 41 |
2016 Junio | 40 | 0 | 40 |
2016 Mayo | 65 | 0 | 65 |
2016 Abril | 31 | 0 | 31 |
2016 Marzo | 29 | 0 | 29 |
2016 Febrero | 36 | 0 | 36 |
2016 Enero | 9 | 0 | 9 |
2015 Diciembre | 31 | 0 | 31 |
2015 Noviembre | 28 | 0 | 28 |
2015 Octubre | 18 | 0 | 18 |
2015 Septiembre | 22 | 0 | 22 |
2015 Agosto | 28 | 0 | 28 |
2015 Julio | 27 | 0 | 27 |
2015 Junio | 2 | 0 | 2 |
2015 Mayo | 15 | 0 | 15 |
2015 Febrero | 1 | 0 | 1 |